Provectus Biopharmaceuticals, Inc.
PVCT · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.26 | -0.07 | 0.18 | -0.04 |
| FCF Yield | -2.25% | -1.66% | -2.60% | -1.81% |
| EV / EBITDA | 0.00 | -18.67 | -40.31 | -22.84 |
| Quality | ||||
| ROIC | 0.00% | 53.59% | 44.07% | 83.84% |
| Gross Margin | 0.00% | 99.19% | -36.62% | 96.76% |
| Cash Conversion Ratio | 0.62 | 0.28 | 0.96 | 0.38 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.48% | -18.39% | -13.22% | -14.55% |
| Free Cash Flow Growth | -60.55% | 52.16% | -19.89% | -61.42% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -1.18 | -1.99 | -1.23 |
| Interest Coverage | 0.00 | -35.07 | -17.25 | -37.46 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -253,749.29 | -143,684.81 | -214,171.16 |